- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01357668
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
May 1, 2023 updated by: Bristol-Myers Squibb
The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.
Study Overview
Status
Recruiting
Conditions
Study Type
Observational
Enrollment (Anticipated)
800
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: First line of email MUST contain NCT# & Site#. Only trial site that are recruiting have contact information at this time
Study Locations
-
-
-
Innsbruck, Austria, A-6020
- Recruiting
- Local Institution - 0002
-
-
-
-
Sao Paulo
-
Botucatu, Sao Paulo, Brazil, 18618-970
- Recruiting
- Local Institution - 0010
-
-
-
-
Quebec
-
Montreal, Quebec, Canada, H4A 3J1
- Recruiting
- Local Institution - 0011
-
-
-
-
-
Copenhagen, Denmark, 2100
- Recruiting
- Local Institution - 0012
-
-
-
-
-
Paris Cedex 15, France, 75743
- Recruiting
- Local Institution - 0005
-
-
-
-
-
Bad Bramstedt, Germany, 24576
- Completed
- Local Institution - 0003
-
-
-
-
-
Thessaloniki, Greece, 54642
- Recruiting
- Local Institution - 0016
-
-
-
-
-
Budapest, Hungary, H-1023
- Recruiting
- Local Institution - 0017
-
-
-
-
-
Jerusalem, Israel, 91031
- Completed
- Local Institution - 0014
-
-
-
-
-
Genova, Italy, 16147
- Recruiting
- Local Institution - 0015
-
-
-
-
-
Riga, Latvia, LV-1007
- Recruiting
- Local Institution - 0018
-
-
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44620
- Recruiting
- Local Institution - 0006
-
-
-
-
-
Utrecht, Netherlands, 3584 EA
- Recruiting
- Local Institution - 0019
-
-
-
-
-
Lima, Peru, 1
- Recruiting
- Local Institution - 0007
-
-
-
-
-
Lisboa, Portugal, 1600
- Recruiting
- Local Institution - 0020
-
-
-
-
-
Bayamon, Puerto Rico, PR 960
- Completed
- Local Institution - 0023
-
-
-
-
-
Cluj-Napoca, Romania
- Recruiting
- Local Institution - 0021
-
-
-
-
-
Moscow, Russian Federation, 119991
- Terminated
- Local Institution
-
-
-
-
-
Riyadh 11426, Saudi Arabia, 11426
- Recruiting
- Local Institution - 0024
-
-
-
-
-
Piestany, Slovakia
- Recruiting
- Local Institution - 0022
-
-
-
-
Gauteng
-
Pretoria, Gauteng, South Africa, 0002
- Recruiting
- Local Institution - 0009
-
-
-
-
-
Barcelona, Spain, 08035
- Recruiting
- Local Institution - 0004
-
-
-
-
-
Bristol, United Kingdom, BS2 8BJ
- Completed
- Local Institution - 0013
-
-
-
-
New Jersey
-
Princeton, New Jersey, United States, 08540
- Recruiting
- Bristol-Myers Squibb, Active
-
Contact:
- Mr Bristol-Myers Squibb, Site 0001
- Phone Number: 609-252-7230
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 17 years (Child)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Pediatric rheumatology clinics
Description
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
- Diagnosis of JIA (any subtype)
- Age < 18 years at the time of enrollment unless currently or previously enrolled in an abatacept clinical trial and received abatacept
- Receiving Abatacept at the time of enrollment as per treating physician's decision or received abatacept in a clinical trial
- Parent or legally acceptable representative willing to participate in the study and sign the informed consent
Exclusion Criteria:
- Pregnant or nursing female at the time of enrollment
- Prior malignancies if the patient has not been malignancy free for at least 5 years.
- Any serious acute or chronic medical condition other than JIA, including chronic infection, which would compromise the patient's ability to participate in the study
- Known poor compliance with clinic visits (based on physician judgment)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Patients with JIA who are treated with Abatacept
Patients with JIA who are treated with Abatacept according to physicians'/families' decisions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence rate of serious infections
Time Frame: 10 years
|
10 years
|
Incidence rate of malignancies
Time Frame: 10 years
|
10 years
|
Incidence rate of autoimmune disorders
Time Frame: 10 years
|
10 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of serious adverse events
Time Frame: 10 years
|
10 years
|
Number of targeted infections (Epstein-Barr virus, cytomegalovirus, papilloma virus, herpes zoster, tuberculosis and opportunistic infections)
Time Frame: 10 years
|
10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 30, 2013
Primary Completion (Anticipated)
January 2, 2029
Study Completion (Anticipated)
January 2, 2029
Study Registration Dates
First Submitted
May 19, 2011
First Submitted That Met QC Criteria
May 20, 2011
First Posted (Estimate)
May 23, 2011
Study Record Updates
Last Update Posted (Actual)
May 3, 2023
Last Update Submitted That Met QC Criteria
May 1, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IM101-240
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Juvenile Idiopathic Arthritis
-
University of AarhusAarhus University HospitalCompletedPolyarticular Juvenile Rheumatoid Arthritis | Systemic Juvenile Idiopathic Arthritis | Juvenile Idiopathic Arthritis, OligoarthritisDenmark
-
Institut National de la Santé Et de la Recherche...CompletedSystemic-Onset Juvenile Idiopathic ArthritisFrance
-
GeneScience Pharmaceuticals Co., Ltd.Not yet recruitingActive Systemic Juvenile Idiopathic ArthritisChina
-
Novartis PharmaceuticalsCompletedSystemic Juvenile Idiopathic Arthritis (SJIA)Italy, Russian Federation, Turkey, Belgium, Spain, Germany, France, Israel, Canada, United States, Hungary, Austria, Brazil, Sweden, Netherlands, Poland
-
Novartis PharmaceuticalsPediatric Rheumatology International Trials OrganizationCompletedSystemic Juvenile Idiopathic Arthritis With Active FlareUnited States, Argentina, Canada, Switzerland, Germany, Israel, South Africa, Belgium, Italy, Spain, France, Brazil, Turkey, Hungary, Poland, Norway, Sweden, Netherlands, Peru
-
University of British ColumbiaUniversity of Manitoba; The Hospital for Sick Children; McGill University Health... and other collaboratorsRecruiting
-
AbbVieCompletedPolyarticular Juvenile Idiopathic Arthritis
-
NovartisCompletedArthritis, Juvenile RheumatoidItaly
-
Assistance Publique - Hôpitaux de ParisRecruitingJuvenile Idiopathic Arthritis (JIA)France
-
AbbVieRecruitingJuvenile Idiopathic Arthritis (JIA)United States, Germany, Hungary, Israel, Puerto Rico, Spain, Japan, Canada, Italy, Sweden